Advertisement
Advertisement

GOSS

GOSS logo

Gossamer Bio, Inc. Common Stock

0.17
USD
Sponsored
0.00
-1.40%
Jun 24, 15:59 UTC -4
Closed
exchange

After-Market

0.17

0.00
+1.18%

GOSS Earnings Reports

Positive Surprise Ratio

GOSS beat 14 of 30 last estimates.

47%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$5.26M
/
-$0.12
Implied change from Q1 26 (Revenue/ EPS)
-68.99%
/
-40.00%
Implied change from Q2 25 (Revenue/ EPS)
-54.24%
/
-29.41%

Gossamer Bio, Inc. Common Stock earnings per share and revenue

On May 15, 2026, GOSS reported earnings of -0.20 USD per share (EPS) for Q1 26, missing the estimate of -0.16 USD, resulting in a -18.62% surprise. Revenue reached 16.95 million, compared to an expected 5.58 million, with a 204.05% difference. The market reacted with a -3.96% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 5.26 million USD, implying an decrease of -40.00% EPS, and decrease of -68.99% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, Gossamer Bio, Inc. Common Stock reported EPS of -$0.20, missing estimates by -18.62%, and revenue of $16.95M, 204.05% above expectations.
The stock price moved down -3.96%, changed from $0.34 before the earnings release to $0.33 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 7 analysts, Gossamer Bio, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $5.26M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement